Oxytocin receptor ligands: a survey of the patent literature

Bibliography

• Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001;81:629-83
   PubMed Web of Science ®Google Scholar
• Nishimori K, Young LJ, Guo Q, et al. Oxytocin is required for nursing but is not essential for parturition or reproductive behavior. Proc Natl Acad Sci USA 1996;93:11699-704
   PubMed Web of Science ®Google Scholar
• Takayanagi Y, Yoshida M, Bielsky IF, et al. Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. Proc Natl Acad Sci USA 2005;102:16096-101
   PubMed Web of Science ®Google Scholar
• Gorbulev V, Buchner H, Akhundova A, et al. Molecular cloning and functional characterization of V2 [8-lysine] vasopressin and oxytocin receptors from a pig kidney cell line. Eur J Biochem 1993;215:1-7
   PubMedGoogle Scholar
• Akerlund M, Bossmar T, Brouard R, et al. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. Br J Obstet Gynaecol 1999;106:1047-53
   PubMedGoogle Scholar
• Ku CY, Qian A, Wen Y, et al. Oxytocin stimulates myometrial guanosine triphosphatase and phospholipase-C activities via coupling to G alpha q/11. Endocrinology 1995;136:1509-15
   PubMed Web of Science ®Google Scholar
• Strakova Z, Soloff MS. Coupling of oxytocin receptor to G proteins in rat myometrium during labor: gi receptor interaction. Am J Physiol 1997;272:E870-6
   PubMed Web of Science ®Google Scholar
• Zingg HH, Laporte SA. The oxytocin receptor. Trends Endocrinol Metab 2003;14:222-7
   PubMed Web of Science ®Google Scholar
• Fuchs AR, Fuchs F, Husslein P, et al. Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor. Science 1982;215:1396-8
   PubMed Web of Science ®Google Scholar
• Blanks AM, Shmygol A, Thornton S. Regulation of oxytocin receptors and oxytocin receptor signaling. Semin Reprod Med 2007;25:52-9
   PubMed Web of Science ®Google Scholar
• Smith MP, Ayad VJ, Mundell SJ, et al. Internalization and desensitization of the oxytocin receptor is inhibited by Dynamin and clathrin mutants in human embryonic kidney 293 cells. Mol Endocrinol 2006;20:379-88
   PubMedGoogle Scholar
• Devost D, Zingg HH. Identification of dimeric and oligomeric complexes of the human oxytocin receptor by co-immunoprecipitation and bioluminescence resonance energy transfer. J Mol Endocrinol 2003;31:461-71
   PubMed Web of Science ®Google Scholar
• Terrillon S, Durroux T, Mouillac B, et al. Oxytocin and Vasopressin V1a and V2 Receptors Form Constitutive Homo- and Heterodimers during Biosynthesis. Mol Endocrinol 2003;17:677-91
   PubMed Web of Science ®Google Scholar
• Chini B, Manning M. Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges. Biochem Soc Trans 2007;35:737-41
   PubMed Web of Science ®Google Scholar
• Hawtin SR, Ha SN, Pettibone DJ, et al. A Gly/Ala switch contributes to high affinity binding of benzoxazinone-based non-peptide oxytocin receptor antagonists. FEBS Lett 2005;579:349-56
   PubMed Web of Science ®Google Scholar
• Chini B, Manning M, Guillon G. Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an “easy guide” to receptor pharmacology. Prog Brain Res 2008;170:513-7
   PubMed Web of Science ®Google Scholar
• Manning M, Stoev S, Chini B, et al. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V(1a), V(1b), V2; and OT receptors: research tools and potential therapeutic agents. Prog Brain Res 2008;170:473-512
   PubMed Web of Science ®Google Scholar
• Manning M, Cheng LL, Klis WA, et al. Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors. Adv Exp Med Biol 1995;395:559-83
   PubMedGoogle Scholar
• Manning M, Sawyer WH. 4-Threonine-oxytocin: a more active and specific oxytocic agent than oxytocin. Nature 1970;227:715-6
   PubMed Web of Science ®Google Scholar
• Elands J, Barberis C, Jard S, et al. 125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH29;]OVT: a selective oxytocin receptor ligand. Eur J Pharmacol 1988;147:197-207
   PubMed Web of Science ®Google Scholar
• Melin P, Trojnar J, Johansson B, et al. Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J Endocrinol 1986;111:125-31
   PubMed Web of Science ®Google Scholar
• Reversi A, Rimoldi V, Marrocco T, et al. The oxytocin receptor antagonist atosiban inhibits cell growth via a “biased agonist” mechanism. J Biol Chem 2005;280:16311-8
   PubMed Web of Science ®Google Scholar
• Nilsson L, Reinheimer T, Steinwall M, et al. FE 200 440: a selective oxytocin antagonist on the term-pregnant human uterus. BJOG 2003;110:1025-8
   PubMed Web of Science ®Google Scholar
• Pierzynski P, Lemancewicz A, Reinheimer T, et al. Inhibitory effect of barusiban and atosiban on oxytocin-induced contractions of myometrium from preterm and term pregangt women. J Soc Gynecol Investig 2004;11
   PubMedGoogle Scholar
• Gimpl G, Postina R, Fahrenholz F, et al. Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin. Eur J Pharmacol 2005;510:9-16
   PubMed Web of Science ®Google Scholar
• Flouret G, Wilson L. Oxytocin antagonist. US19945373089; 1994
   Google Scholar
• Pak SC, Bertoncini D, Meyer W, et al. Comparison of binding affinity of oxytocin antagonists to human and rat uterine oxytocin receptors and their correlation to the rat uterine oxytocic bioassay. Biol Reprod 1994;51:1140-4
   PubMed Web of Science ®Google Scholar
• Williams PD, Bock MG, Evans BE, et al. Progress in the development of oxytocin antagonists for use in preterm labor. Adv Exp Med Biol 1998;449:473-9
   PubMed Web of Science ®Google Scholar
• Manning M, Miteva K, Pancheva S, et al. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban. Int J Pept Protein Res 1995;46:244-52
   PubMedGoogle Scholar
• Terrillon S, Cheng LL, Stoev S, et al. Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V1;(a) receptors. J Med Chem 2002;45:2579-88
   PubMed Web of Science ®Google Scholar
• Albizu L, Teppaz G, Seyer R, et al. Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem 2007;50:4976-85
   PubMed Web of Science ®Google Scholar
• Chini B, Chinol M, Cassoni P, et al. Improved radiotracing of oxytocin receptor-expressing tumours using the new [111;In]-DOTA-Lys8;-deamino-vasotocin analogue. Br J Cancer 2003;89:930-6
   PubMed Web of Science ®Google Scholar
• Bussolati G, Cassoni P, Chini B. Cytotoxic or radioactive conjugates able to bind to oxytocin receptors. WO2002098447; 2002
   Google Scholar
• Barth T, Jost K, Rychlik I. Milk-ejecting and uterotonic activities of oxytocin analogues in rats. Endocrinol Exp 1975;9:35-42
   PubMedGoogle Scholar
• Atke A, Vilhardt H. Uterotonic activity and myometrial receptor affinity of 1-deamino-1-carba-2-tyrosine(O-methyl)-oxytocin. Acta Endocrinol Copenh 1987;115:155-60
   PubMedGoogle Scholar
• Engstrom T, Barth T, Melin P, et al. Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Eur J Pharmacol 1998;355:203-10
   PubMed Web of Science ®Google Scholar
• Stymiest JL, Mitchell BF, Wong S, et al. Synthesis of oxytocin analogues with replacement of sulfur by carbon gives potent antagonists with increased stability. J Org Chem 2005;70:7799-809
   PubMed Web of Science ®Google Scholar
• Hawtin SR, Howard HC, Wheatley M. Identification of an extracellular segment of the oxytocin receptor providing agonist-specific binding epitopes. Biochem J 2001;354:465-72
   PubMed Web of Science ®Google Scholar
• Wesley VJ, Hawtin SR, Howard HC, et al. Agonist-specific, high-affinity binding epitopes are contributed by an arginine in the N-terminus of the human oxytocin receptor. Biochemistry 2002;41:5086-92
   PubMed Web of Science ®Google Scholar
• Evans BE, Lundell GF, Gilbert KF, et al. Nanomolar-affinity, non-peptide oxytocin receptor antagonists. J Med Chem 1993;36:3993-4005
   PubMed Web of Science ®Google Scholar
• Pettibone DJ, Guidotti M, Harrell CM, et al. Progress in the development of oxytocin antagonists for use in preterm labor. Adv Exp Med Biol 1995;395:601-12
   PubMedGoogle Scholar
• Yamamura Y, Ogawa H, Chihara T, et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 1991;252:572-4
   PubMed Web of Science ®Google Scholar
• Evans BE, Leighton JL, Rittle KE, et al. Orally active, nonpeptide oxytocin antagonists. J Med Chem 1992;35:3919-27
   PubMed Web of Science ®Google Scholar
• Merck & Co. Tocolytic oxytocin receptor antagonists. WO1996022775; 1996
   Google Scholar
• Merck & Co. Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists. US19975756497; 1997
   Google Scholar
• Liddle J, Allen MJ, Borthwick AD, et al. The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett 2008;18:90-4
   PubMed Web of Science ®Google Scholar
• McCafferty GP, Pullen MA, Wu C, et al. Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat. Am J Physiol Regul Integr Comp Physiol 2007;293:R299-305
   Web of Science ®Google Scholar
• Ferring BV. Piperazines as oxtocin agonists. WO2005023812; 2005
   Google Scholar
• Ferring BV. Benzamide derivatives as oxytocin agonists and vasopressin antagonists. WO2004072083; 2004
   Google Scholar
• Serradeil-Le GC, Valette G, Foulon L, et al. SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3- dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor. J Pharmacol Exp Ther 2004;309:414-24
   PubMed Web of Science ®Google Scholar
• Serono Int. Triazoles as oxytocin antagonists. WO2003053437; 2003
   Google Scholar
• Serono Int. Pyrrolidine ester derivatives with oxytocin modulating activity. WO2002074741; 2002
   Google Scholar
• Serono Int. Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptors antagonists. WO2002102799; 2002
   Google Scholar
• Applied Research Systems ARS. Pyrrolidine derivatives as oxytocin antagonists. US20067115754; 2006
   Google Scholar
• Cirillo R, Gillio TE, Schwarz MK, et al. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2′-methyl[1,1′-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. J Pharmacol Exp Ther 2003;306:253-61
   PubMed Web of Science ®Google Scholar
• Pitt GR, Batt AR, Haigh RM, et al. Non-peptide oxytocin agonists. Bioorg Med Chem Lett 2004;14:4585-9
   PubMed Web of Science ®Google Scholar
• Ferring BV. Diazacycloalkanes as oxytocin agonists. WO2003016316; 2003
   Google Scholar
• Ferring BV. Oxytocin agonists. WO2003000692; 2003
   Google Scholar
• Smith R. Parturition. N Engl J Med 2007;356:271-83
   PubMed Web of Science ®Google Scholar
• Slattery MM, Morrison JJ. Preterm delivery. Lancet 2002;360:1489-97
   PubMed Web of Science ®Google Scholar
• Kam KY, Lamont RF. Developments in the pharmacotherapeutic management of spontaneous preterm labor. Expert Opin Pharmacother 2008;9:1153-68
   PubMed Web of Science ®Google Scholar
• Grignaffini A, Soncini E, Ronzoni E, et al. Clinical practice evaluation of combination of atosiban, ritodrine and ketoprofen for inhibiting preterm labor. Minerva Ginecol 2007;59:481-9
   PubMedGoogle Scholar
• Goodwin TM, Paul R, Silver H, et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. Am J Obstet Gynecol 1994;170:474-8
   PubMed Web of Science ®Google Scholar
• Romero R, Sibai BM, Sanchez-Ramos L, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 2000;182:1173-83
   PubMed Web of Science ®Google Scholar
• Papatsonis D, Flenady V, Cole S, et al. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev 2005;CD004452
   PubMedGoogle Scholar
• Reinheimer TM, Bee WH, Resendez JC, et al. Barusiban, a new highly potent and long-acting oxytocin antagonist: pharmacokinetic and pharmacodynamic comparison with atosiban in a cynomolgus monkey model of preterm labor. J Clin Endocrinol Metab 2005;90:2275-81
   PubMed Web of Science ®Google Scholar
• Simhan HN, Caritis SN. Prevention of preterm delivery. N Engl J Med 2007;357:477-87
   PubMed Web of Science ®Google Scholar
• Ferring International Center SA. Use of antagonists of oxytocin and/or vasopressin in assisted reproduction. WO2006121362; 2006
   Google Scholar
• Cassoni P, Sapino A, Marrocco T, et al. Oxytocin and oxytocin receptors in cancer cells and proliferation. J Neuroendocrinol 2004;16:362-4
   PubMed Web of Science ®Google Scholar
• Copland JA, Jeng YJ, Strakova Z, et al. Demonstration of functional oxytocin receptors in human breast Hs578T cells and their up-regulation through a protein kinase C-dependent pathway. Endocrinology 1999;140:2258-67
   PubMed Web of Science ®Google Scholar
• Bussolati G, Chinol M, Chini B, et al. 111In-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′‘-tetraacetic acid-lys8;-vasotocin: a new powerful radioligand for oxytocin receptor-expressing tumors. Cancer Res 2001;61:4393-7
   PubMed Web of Science ®Google Scholar
• Uvnas-Moberg K, Lundeberg T. Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis. US20040176284; 2004
   Google Scholar
• Quay SC. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders. US20040235956; 2004
   Google Scholar
• Petersson M, Wiberg U, Lundeberg T, et al. Oxytocin decreases carrageenan induced inflammation in rats. Peptides 2001;22:1479-84
   PubMed Web of Science ®Google Scholar
• Iseri SO, Sener G, Saglam B, et al. Oxytocin protects against sepsis-induced multiple organ damage: role of neutrophils. J Surg Res 2005;126:73-81
   PubMed Web of Science ®Google Scholar
• Uvnas-Moberg K, Lundeberg T. Use of substances with oxytocin activity for the preparation of a pharmaceutical composition against inflammation. WO2003017922; 2003
   Google Scholar
• Ferring BV. Use of substances having oxtocin antagonistic properties for the preparation of a medicament for treating hypertension. WO2005070449; 2005
   Google Scholar
• Paquin J, Danalache BA, Jankowski M, et al. Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes. Proc Natl Acad Sci USA 2002;99:9550-5
   PubMed Web of Science ®Google Scholar
• Gutkovska J, Paquin J, Danalache B, et al. Oxytocin as cardiomyogenesis inducer and uses thereof. US20060205636; 2006
   Google Scholar
• Elabd C, Basillais A, Beaupied H, et al. Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis. Stem Cells 2008
   PubMedGoogle Scholar
• Copland JA, Kirk LI, Simmons DJ, et al. Clinical use of oxytocin alone or in combination to treat bone disorders. US20016333313; 2001
   Google Scholar
• Uvnas-Moberg K, Lundegardh B. Use of a substance with oxytocin activity in order to stimulate plant growth. US20060052248; 2006
   Google Scholar
• Yeomans DC, Angst MS, Frey WH, Jacobs DI. Methods for treatment of headaches by administration of oxytocin. US20070054843; 2007
   Google Scholar
• Nastech Pharmaceutical Company Inc. Compositions and methods for the treatment of psychiatric disorders. US20070032410; 2007
   Google Scholar
• Hollander E. Treatment of autism and similar disorders. US20060105939; 2006
   Google Scholar
• Nastech Pharmaceutical Company Inc. Pharmaceutical compositions comprising oxytocin or an analog for the treatment of autism. WO2008042452; 2008
   Google Scholar
• Uvnas-Moberg KU, Lundeberg T, Petersson M. Use of fragments of oxytocin for the preparation of a pharmaceutical composition in order to create eustasis. US20040259805; 2004
   Google Scholar
• Kosfeld M, Heinrichs M, Zak PJ, et al. Oxytocin increases trust in humans. Nature 2005;435:673-6
   PubMed Web of Science ®Google Scholar
• Prevalence of autism spectrum disorders-autism and developmental disabilities monitoring network, 14 sites, United States, 2002. MMWR Surveill Summ 2007;56:12-28
   PubMedGoogle Scholar
• Insel TR, O'Brien DJ, Leckman JF. Oxytocin, vasopressin, and autism: is there a connection? Biol Psychiatry 1999;45:145-57
   PubMed Web of Science ®Google Scholar
• Modahl C, Green L, Fein D, et al. Plasma oxytocin levels in autistic children. Biol Psychiatry 1998;43:270-7
   PubMed Web of Science ®Google Scholar
• Marazziti D, Dell'Osso MC. The role of oxytocin in neuropsychiatric disorders. Curr Med Chem 2008;15:698-704
   PubMed Web of Science ®Google Scholar
• Hollander E, Bartz J, Chaplin W, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry 2007;61:498-503
   PubMed Web of Science ®Google Scholar
• Born J, Lange T, Kern W, et al. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002;5:514-6
   PubMed Web of Science ®Google Scholar
• Baumgartner T, Heinrichs M, Vonlanthen A, et al. Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 2008;58:639-50
   PubMed Web of Science ®Google Scholar
• Heinrichs M, Meinlschmidt G, Wippich W, et al. Selective amnesic effects of oxytocin on human memory. Physiol Behav 2004;83:31-8
   PubMed Web of Science ®Google Scholar
• Fisk NM, Atun R. Market failure and the poverty of new drugs in maternal health. PLoS Med 2008;5:e22
   PubMed Web of Science ®Google Scholar
• Opar A. Search for potential autism treatments turns to ‘trust hormone’. Nat Med 2008;14:353
   PubMed Web of Science ®Google Scholar
• Ferring BV. Stabilized composition for oral administration of peptides. US19975922680; 1997
   Google Scholar
• Abelman Frayne & Schwab. Pharmaceutical composition containing a small or medium size peptide. US20010027177; 2001
   Google Scholar
• Nastech Pharmaceutical Co. Tight junction modulating peptides for enhanced mucosal delivery of therapeutic compounds. US20070154449; 2007
   Google Scholar
• Aneja A, Tierney E. Autism: the role of cholesterol in treatment. Int Rev Psychiatry 2008;20:165-70
   PubMed Web of Science ®Google Scholar
• Tierney E, Bukelis I, Thompson RE, et al. Abnormalities of cholesterol metabolism in autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet 2006;141B:666-8
   PubMed Web of Science ®Google Scholar
• Sikora DM, Pettit-Kekel K, Penfield J, et al. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J Med Genet A 2006;140:1511-8
   PubMedGoogle Scholar
• Gimpl G, Klein U, Reilander H, et al. Expression of the human oxytocin receptor in baculovirus-infected insect cells: high-affinity binding is induced by a cholesterol-cyclodextrin complex. Biochemistry 1995;34:13794-801
   PubMed Web of Science ®Google Scholar
• Klein U, Gimpl G, Fahrenholz F. Alteration of the myometrial plasma membrane cholesterol content with beta-cyclodextrin modulates the binding affinity of the oxytocin receptor. Biochemistry 1995;34:13784-93
   PubMed Web of Science ®Google Scholar
• Gimpl G, Burger K, Fahrenholz F. Cholesterol as modulator of receptor function. Biochemistry 1997;36:10959-74
   PubMed Web of Science ®Google Scholar
• Guzzi F, Zanchetta D, Cassoni P, et al. Localization of the human oxytocin receptor in caveolin-1 enriched domains turns the receptor-mediated inhibition of cell growth into a proliferative response. Oncogene 2002;21:1658-67
   PubMed Web of Science ®Google Scholar
• Neumann ID. Brain oxytocin: a key regulator of emotional and social behaviours in both females and males. J Neuroendocrinol 2008;20:858-65
   PubMed Web of Science ®Google Scholar
• Mouillac B, Chini B, Balestre MN, et al. The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. J Biol Chem 1995;270:25771-7
   PubMed Web of Science ®Google Scholar
• Thibonnier M, Preston JA, Dulin N, et al. The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology 1997;138:4109-22
   PubMed Web of Science ®Google Scholar
• Derick S, Cheng LL, Voirol MJ, et al. [1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Endocrinology 2002;143:4655-64
   PubMed Web of Science ®Google Scholar